Evidence map›Paper›PMID 29255726›Full record

ArticleOpen forum infectious diseases2017

The Impact of Human Pegivirus on CD4 Cell Count in HIV-Positive Persons in Botswana.

Kombo F N'Guessan, Motswedi Anderson, Bonolo Phinius, Sikhulile Moyo, Alyyah Malick, Tshepiso Mbangiwa, Wonderful T Choga, Joseph Makhema, Richard Marlink, Max Essex and 3 more

Open access · goldAbstract read
In one paragraph

Article in Open forum infectious diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Molecular characterization and frequency of human pegivirus type 1 (HPgV-1) in kidney transplant recipients from Central-West Brazil.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024
    Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Kombo F N'GuessanUniversity of Cincinnati College of Medicine, Cincinnati, Ohio.
Motswedi AndersonBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Bonolo PhiniusBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Sikhulile MoyoBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Alyyah MalickBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Tshepiso MbangiwaBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Wonderful T ChogaBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Joseph MakhemaBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Richard MarlinkBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Max EssexBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Rosemary MusondaBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Simani GaseitsiweBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Jason T BlackardUniversity of Cincinnati College of Medicine, Cincinnati, Ohio.
Botswana Harvard AIDS Institute Partnership · BWHarvard University · USUniversity of Cincinnati Medical Center · USHarvard College Observatory · USUniversity of Botswana · BW

Funding

Stem Cell/Organoid and Genome Editing CoreP30DK078392 · NIDDK · CINCINNATI CHILDRENS HOSP MED CTR · PI Alexander Miethke · 2007 to 2026
$24.4M
Partnership for Global Health Research Training Program (Renewal)-Supplement for OBSSR, NCI, NCI-AIDS and NIDCDD43TW010543 · FIC · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Wafaie W Fawzi, DAVIDSON HOWES HAMER · 2017 to 2026
$12.1M
Training in HIV Genomics, Treatment, and Cure Research in BotswanaD43TW009610 · FIC · THE BOTSWANA HARVARD HEALTH PARTNERSHIP · PI SHAHIN LOCKMAN, Joseph Moeketsi Makhema · 2013 to 2026
$4.4M
FIC NIH HHS D43 TW009610FIC NIH HHS D43 TW010543NIDDK NIH HHS P30 DK078392Wellcome Trust
6 · The paper itself

Abstract

backgroundHuman pegiviruses (HPgV)-formerly known as hepatitis G virus or GB virus C (GBV-C)-are common single-stranded RNA viruses that may have a beneficial impact on slowing HIV disease progression. The data on HPgV in resource-limited regions such as Sub-Saharan Africa are scarce. Thus, we conducted the first study of HPgV in Botswana as part of a natural history study of HIV subtype C disease progression.

methodsPlasma samples from 133 HIV-positive adults were evaluated for HPgV RNA, and the 5'UTR was sequenced to determine the HPgV genotype.

resultsHPgV RNA was detected in 41 (30.8%) individuals. While the presence of HPgV RNA had no impact on baseline HIV viral load, a significant difference in baseline CD4 cell count was observed. HPgV genotypes were determined for 27 individuals and included 5 individuals (18.5%) with genotype 1 and 22 (81.5%) with genotype 5. Baseline CD4 cell counts were significantly higher for persons infected with HPgV genotype 5 compared with genotype 1.

conclusionsThese data suggest that HPgV infection is common among HIV-positive individuals in Botswana and has a significant impact on CD4 cell count. This difference in CD4 cell count based on HPgV genotype suggests that HPgV genotype should be evaluated as a possible predictor of HIV disease progression and highlights the need for additional studies of this virus in resource-limited settings.

Indexed as

AfricaBotswanaGB virus C (GBV-C)genotypehepatitis G virusHIVhuman pegivirus (HPgV)

Identifiers

PMID29255726
PMCPMC5726461
OpenAlexW2762595948

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.